Relationship of circulating tumor cells and spleen

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K09160
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Nippon Medical School
• Principal Investigator: Yoshida Hiroshi 日本医科大学, 大学院医学研究科, 教授 (60246999)
• Co-Investigator(Kenkyū-buntansha): 山田 岳史 日本医科大学, 医学部, 准教授 (50307948)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 門脈 / 脾臓 / リキッドバイオプシー

Outline of Final Research Achievements

Several papers on liquid biopsy and portal hemodynamics and spleen are presented. And, the research using urinary circulatory DNA was also started. Although circulating DNA was already known in the urine, we found that the amount of cfDNA extracted from 20 mL of urine is higher than that of cfDNA extracted from 1 mL of plasma, and that urine-derived cfDNA is more accurate than using blood-derived cfDNA when performing RAS mutation analysis.The mRNA expression profiles of free tumor cells (Circulating tumor cell: CTC) collected from peripheral blood are continuously compared and examined.

Free Research Field

消化器外科

Academic Significance and Societal Importance of the Research Achievements

大量肝切除前に門脈塞栓術を行う消化器癌患者を対象とし、門脈塞栓時の大動脈血（腹腔動脈直上）、脾静脈血、上腸間膜静脈血、門脈血、末梢血から採取された遊離した腫瘍細胞(Circulating tumor cell: CTC)のmRNA発現プロファイルを比較することで、脾臓内で免疫細胞と腫瘍細胞がどのような反応を起こしているかを推測している。本研究により脾臓の持つ抗腫瘍作用のメカニズムが解明されれば、新たな免疫治療法の開発に繋がる可能性がある。